Navigation Links
Peregrine reports new study from Duke shows anti-HIV potential of targeting PS on cells
Date:4/5/2010

Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today announced the publication of data showing phosphatidylserine (PS)-targeting antibodies can block one of the key ways the AIDS virus gains entry into certain blood cells. The data were generated by scientists at Duke University as part of their ongoing AIDS vaccine research. The article titled "Anti-Phospholipid Human Monoclonal Antibodies Inhibit CCR5-Tropic HIV-1 and Induces β-Chemokines" is available online today and will be published in the April 12, 2010 edition of the Journal of Experimental Medicine. Peregrine's PS-targeting antibodies are currently in clinical development for the treatment of cancer and HCV infections.

In early stage in vitro studies reported by Dr. Anthony Moody of Duke University, lead author of the publication, PS-targeting antibodies developed or licensed by Peregrine blocked HIV from docking with its most commonly used entry point into blood cells--the CCR5 receptor. The antibodies accomplished this indirectly, by binding to white blood cells called monocytes and causing them to secrete proteins called chemokines, which have the ability to block entry of HIV into the cell. In the presence of monocytes, the antibodies prevented HIV infection in vitro 85% of the time in these studies.

Investigators believe the finding has particular strategic importance because most HIV strains use the CCR5 receptor to gain entry into a cell. In addition, it is one of the earliest events in the process of infection, so being able to intervene at this juncture could potentially be clinically useful.

Dr. Philip Thorpe, professor of pharmacology at UT Southwestern Medical Center, a pioneer in the development of PS-targeting therapies and an author of the new publication commented, "This study from our colleagues at Duke University illuminates another intriguing aspect of phospholipid-targeting antibodies--the diversity of their anti-viral mechanisms and broad spectrum anti-viral potential. The PS-targeting antibodies in this study showed potent ability to induce specific effects that impact viruses, in this case by stimulating the production of immune-related proteins that block the entry of HIV into cells. We look forward to the results of additional studies of these antibodies that are planned at Duke."

Barton Haynes, M.D., director of the Duke Human Vaccine Institute and senior author of the study commented, "These results indicate that targeting a host cell lipid such as PS as an anti-viral strategy is a promising concept of relevance to new therapeutic and possibly prophylactic innovations for HIV."

Peregrine's most advanced PS-targeting antibody bavituximab is currently being studied in a clinical trial for the treatment of patients co-infected with hepatitis C virus (HCV) and HIV. Earlier Phase I studies in HCV patients showed that bavituximab was well tolerated and it exhibited encouraging signs of anti-viral activity. Under a major biodefense initiative, bavituximab and a fully human equivalent antibody are also in preclinical development for the treatment of viral hemorrhagic fevers (VHF). In November, 2009 Peregrine researchers presented positive data on progress in this program, showing that the PS-targeting antibodies increase survival in a model of lethal VHF infection.

"This publication is the latest in a series of presentations and publications that supports the potential of PS as a target in HIV infection and provides new insights into the unique mechanisms of action of our PS-targeting antibodies," said Steven W. King, president and CEO of Peregrine. "While past studies have focused on the broad nature of the PS target, these new data reveal that some of these antibodies may also have highly specific effects."


'/>"/>

Contact: Barbara Lindheim
blindheim@biocompartners.com
212-918-4650
BioCom Partners
Source:Eurekalert

Related biology news :

1. Nature Medicine study shows Peregrines bavituximab can cure lethal virus infections
2. Peregrines PS-targeting antibodies highlighted in AACR Annual Meeting studies
3. BIO-key Reports Second Quarter 2007 Results
4. Communication Intelligence Corporation Reports Second Quarter 2007 Financial Results
5. Emory paleontologist reports discovery of carnivorous dinosaur tracks in Australia
6. BIO-key Reports Third Quarter 2007 Results
7. WHRC releases 4 key reports
8. Rong Li Lab reports protein interactions of MAP kinase signaling pathway
9. UVA reports surprising findings related to myotonic muscular dystrophy
10. Drug aimed at 2 bioterror agents blocks live viral infection, Weill Cornell team reports
11. MIT reports new twist in microRNA biology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/15/2016)... , Nov 15, 2016 Research and ... Global Forecast to 2021" report to their offering. ... ... USD 16.18 Billion by 2021 from USD 6.21 Billion in 2016, ... Growth of the bioinformatics market is driven by the ...
(Date:6/22/2016)... 22, 2016  The American College of Medical Genetics and ... Magazine as one of the fastest-growing trade shows during ... the Bellagio in Las Vegas . ... of growth in each of the following categories: net square ... number of attendees. The 2015 ACMG Annual Meeting was ranked ...
(Date:6/20/2016)... June 20, 2016 Securus Technologies, a ... solutions for public safety, investigation, corrections and monitoring ... involved, it has secured the final acceptance by ... for Managed Access Systems (MAS) installed. Furthermore, Securus ... to be installed by October, 2016. MAS distinguishes ...
Breaking Biology News(10 mins):
(Date:12/8/2016)... , Dec. 8, 2016 Savannah River ... technologies and selected NewTechBio,s NT-MAX Lake & ... based beneficial bacteria, in conjunction with Hexa Armor/ ... deficiencies with National Pollutant Discharge Elimination System requirements. ... experienced a steady history of elevated pH levels, ...
(Date:12/8/2016)... PHILADELPHIA , Dec. 8, 2016  Partnering to ... ecosystem, Ben Franklin Technology Partners of Southeastern ... Group ("IHG"), the parent company of Independence Blue Cross; ... today announced their intentions for a $6 million funding ... early-stage healthcare startups. Responding to a burgeoning ...
(Date:12/7/2016)... ... 07, 2016 , ... ACEA Biosciences, Inc. presented today updated ... trial for its lead drug candidate, AC0010, at the World Conference on Lung ... determine the safety, antitumor activity, and recommended phase II dosage of AC0010 in ...
(Date:12/7/2016)... ... December 07, 2016 , ... Huffman Engineering, ... become a Wonderware Certified System Integrator Partner. Huffman Engineering is the only ... , “The System Integrator Partner certification gives customers confidence that our engineers are ...
Breaking Biology Technology: